Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA

IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Alimentary Pharmacology & Therapeutics Pub Date : 2024-11-21 DOI:10.1111/apt.18409
Gian Paolo Caviglia, Piero Fariselli, Roberta D'Ambrosio, Piero Colombatto, Elisabetta Degasperi, Gabriele Ricco, Maria Lorena Abate, Giovanni Birolo, Giulia Troshina, Francesco Damone, Barbara Coco, Daniela Cavallone, Riccardo Perbellini, Sara Monico, Giorgio Maria Saracco, Maurizia Rossana Brunetto, Pietro Lampertico, Alessia Ciancio
{"title":"Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA","authors":"Gian Paolo Caviglia, Piero Fariselli, Roberta D'Ambrosio, Piero Colombatto, Elisabetta Degasperi, Gabriele Ricco, Maria Lorena Abate, Giovanni Birolo, Giulia Troshina, Francesco Damone, Barbara Coco, Daniela Cavallone, Riccardo Perbellini, Sara Monico, Giorgio Maria Saracco, Maurizia Rossana Brunetto, Pietro Lampertico, Alessia Ciancio","doi":"10.1111/apt.18409","DOIUrl":null,"url":null,"abstract":"Patients with hepatitis C virus (HCV)-related cirrhosis with sustained virological response (SVR) to direct-acting antivirals (DAA) remain at risk of developing hepatocellular carcinoma (HCC). Recently, serum protein induced by vitamin K absence or antagonist-II (PIVKA-II) has shown promising results as an HCC-predictive biomarker. We aimed to develop and validate a PIVKA-II-based model for HCC risk stratification in cirrhotic patients with SVR to DAA.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"170 1","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/apt.18409","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Patients with hepatitis C virus (HCV)-related cirrhosis with sustained virological response (SVR) to direct-acting antivirals (DAA) remain at risk of developing hepatocellular carcinoma (HCC). Recently, serum protein induced by vitamin K absence or antagonist-II (PIVKA-II) has shown promising results as an HCC-predictive biomarker. We aimed to develop and validate a PIVKA-II-based model for HCC risk stratification in cirrhotic patients with SVR to DAA.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
开发并验证基于 PIVKA-II 的模型,用于对接受 DAA 成功治疗的 HCV 相关性肝硬化患者进行 HCC 风险分层
对直接作用抗病毒药物(DAA)有持续病毒学应答(SVR)的丙型肝炎病毒(HCV)相关肝硬化患者仍有罹患肝细胞癌(HCC)的风险。最近,维生素 K 缺乏或拮抗剂-II(PIVKA-II)诱导的血清蛋白作为 HCC 预测生物标志物显示出了良好的效果。我们旨在开发并验证一种基于 PIVKA-II 的模型,用于对接受 DAA 治疗并获得 SVR 的肝硬化患者进行 HCC 风险分层。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
15.60
自引率
7.90%
发文量
527
审稿时长
3-6 weeks
期刊介绍: Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
期刊最新文献
Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease? Editorial: Updated COVID-19 Boosters-Tailoring Protection for Patients With IBD. Authors' Reply. Review Article: Green Management of IBD-New Paradigms for an Eco-Friendly Approach. Subcutaneous Infliximab Concentration Thresholds for Mucosal and Transmural Healing in Patients With Crohn's Disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1